/MXCT.L

MXCT.L Stock - MaxCyte, Inc.

Q: What is the analyst price target for MXCT.L?

Analyst price target information is not currently available for MXCT.L.

Q: What is MXCT.L's market cap?

Market capitalization information is not currently available for MXCT.L.

Healthcare|Medical - Devices|LSE

$147.69-7.69%

$12.31 (-7.69%) • Jun 25

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $162.46

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MXCT.L

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.04

52W High$407.84

52W Low$147.69

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$38.63M	$41.29M	$44.26M	$33.89M	$26.17M
Gross Profit	$31.53M	$36.55M	$39.16M	$30.25M	$23.40M
Gross Margin	81.6%	88.5%	88.5%	89.2%	89.4%
Operating Income	$-51,197,000	$-48,299,000	$-27,360,500	$-18,188,600	$-11,056,700
Net Income	$-41,055,000	$-37,923,000	$-19,781,100	$-20,126,600	$-12,642,000
Net Margin	-106.3%	-91.8%	-44.7%	-59.4%	-48.3%
EPS	$-0.39	$-0.37	$-0.19	$-0.22	$-0.18

Company Overview

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Visit Website

Earnings History & Surprises

MXCT.L

Beat Rate

79%

Last 14 quarters

Avg Surprise

+25.3%

EPS vs Estimate

Beats / Misses

11/3

Last 12 quarters

Latest EPS

$-0.10

Q2 2025

EPS Surprise History

Q3 23

-6.5%

$-0.08vs$-0.08

Q4 23

-8.0%

$-0.09vs$-0.08

Q1 24

+25.0%

$-0.04vs$-0.05

Q2 24

+26.4%

$-0.07vs$-0.10

Q3 24

+27.4%

$-0.07vs$-0.10

Q4 24

+35.2%

$-0.08vs$-0.13

Q1 25

+24.8%

$-0.08vs$-0.11

Q2 25

+6.3%

$-0.10vs$-0.10

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2025	May 7, 2025	$-0.10	$-0.10	+6.3%	✓ BEAT
Q1 2025	Mar 11, 2025	$-0.11	$-0.08	+24.8%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.13	$-0.08	+35.2%	✓ BEAT
Q3 2024	Aug 7, 2024	$-0.10	$-0.07	+27.4%	✓ BEAT
Q2 2024	May 8, 2024	$-0.10	$-0.07	+26.4%	✓ BEAT
Q1 2024	Mar 13, 2024	$-0.05	$-0.04	+25.0%	✓ BEAT
Q4 2023	Nov 9, 2023	$-0.08	$-0.09	-8.0%	✗ MISS
Q3 2023	Aug 10, 2023	$-0.08	$-0.08	-6.5%	✗ MISS
Q2 2023	May 11, 2023	$-0.09	$-0.07	+25.6%	✓ BEAT
Q1 2023	Mar 16, 2023	$-0.06	$-0.02	+64.3%	✓ BEAT
Q3 2022	Sep 30, 2022	$-0.08	$-0.05	+43.2%	✓ BEAT
Q2 2022	Jun 30, 2022	$-0.06	$-0.06	-1.2%	✗ MISS
Q1 2022	Mar 31, 2022	$-0.05	$-0.03	+40.5%	✓ BEAT
Q4 2021	Dec 31, 2021	—	$-0.04	—	—
Q3 2021	Sep 30, 2021	$-0.04	$-0.02	+51.7%	✓ BEAT
Q2 2021	Jun 30, 2021	—	$-0.04	—	—
Q1 2021	Mar 31, 2021	—	$-0.06	—	—
Q4 2020	Dec 31, 2020	—	$-0.03	—	—
Q3 2020	Sep 30, 2020	—	$-0.03	—	—
Q2 2020	Jun 30, 2020	—	$-0.04	—	—